Coalition, the world's first Active Insurance provider designed to prevent digital risk before it strikes, today announced the new Coalition Active Cyber Policy, a reimagined United States surplus ...

NetApp Partners With Google Cloud to Simplify Scaling High-Performance Workloads in the CloudNew features for Google Cloud NetApp Volumes improve support for large workloads, including Vertex ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $460.00. The company’s shares closed yesterday ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Laila Maidan is a Tech and Investing reporter at MarketWatch. She covers the rapid developments in the sector along with actionable investment recommendations and deep dives into valuations.

While my colleagues and most of the industry have been in Geneva, enjoying Watches and Wonders and devouring the sights and sounds of the year’s biggest trade fair, I have been watching on from home ...